Announced Tue, 6 Oct, 2026 · 09:36 IST
Lupin launches world's first triple combo COPD inhaler in India
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.8%1-day move
₹2011.00
prior close
₹2006.10
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.2+0.3+0.3+0.4+0.8-3.7————————
Up moveDown movePending
AI summary
Lupin has launched Formoflo-G MDI in India, the world's first fixed-dose triple combination inhaler for moderate to severe COPD, after approval from India's drug regulator (DCGI). It combines Glycopyrronium, Formoterol and Fluticasone in a single twice-daily dose. The launch targets over 55 million COPD patients in India and strengthens Lupin's respiratory portfolio, where it is ranked number 2 by IQVIA (MAT March 2026).
Likely market impact
Adds a differentiated, first-in-world product to Lupin's respiratory portfolio, potentially boosting India formulation revenues.